



van Oostrom, H., & Knowles, T. G. (2018). The clinical efficacy of EMLA cream for intravenous catheter placement in client-owned dogs. *Veterinary Anaesthesia and Analgesia*, 45(5), 604-608.
<https://doi.org/10.1016/j.vaa.2018.03.009>

Peer reviewed version

License (if available):
CC BY-NC-ND

Link to published version (if available):
[10.1016/j.vaa.2018.03.009](https://doi.org/10.1016/j.vaa.2018.03.009)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the accepted author manuscript (AAM). The final published version (version of record) is available online via Elsevier at DOI: 10.1016/j.vaa.2018.03.009. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/pure/about/ebr-terms>

1 **The clinical efficacy of EMLA cream for intravenous catheter placement in client**
2 **owned dogs.**

3

4 **Abstract**

5 *Objective*

6 Assessing the reaction of client owned dogs to
7 IV catheter placement after applying EMLA or placebo cream for either 30 or 60 minutes.

8 *Study design*

9 Prospective, randomised, blinded, placebo controlled, clinical trial.

10 *Animals*

11 Two hundred and two client owned dogs of various breeds.

12 *Methods*

13 With owner consent, dogs were randomly allocated to one of four treatment groups. Group 1
14 EMLA 60 minutes; Group 2 EMLA 30 minutes; Group 3 Placebo 60 minutes; Group 4
15 Placebo 30 minutes. After the cream was applied for the allocated time an IV catheter was
16 placed and the behavioural reaction of the dog was scored. Reaction score was analysed using
17 a Kruskal Wallis test followed by Mann Whitney tests of the multiple pairwise comparisons,
18 with Bonferroni correction.

19 *Results*

20 A large number of dogs, even in the placebo groups, did not react to intravenous catheter
21 placement. However, the Kruskal Wallis test showed there to be an overall difference
22 between treatment groups (Chi sq = 11.029, df = 3, p = 0.012). The pairwise comparisons
23 showed there to be a lower overall reaction score in the EMLA 60 group compared with the
24 EMLA 30 group and the Placebo 60 group (adjusted p = 0.018 and adjusted p = 0.044,
25 respectively).

26 *Conclusion and clinical relevance*

27 This study shows that EMLA cream applied for 60 minutes reduces the behavioural reaction
28 of dogs to IV catheter placement and therefore this intervention can be advocated for routine
29 use in veterinary medicine to enhance the welfare of dogs undergoing IV catheter placement.

30

31 **Keywords:** EMLA cream, dog, intravenous catheter, venepuncture

32 **Funding:**

33

34 **Introduction**

35 Placement of an intravenous catheter in dogs is a very common procedure in contemporary
36 veterinary medicine, but one which has been shown to be potentially aversive to the animal
37 (Chebroux et al. 2015; Flecknell et al. 1990).

38 The use of EMLA cream, a eutectic mixture of the local anaesthetics lidocaine and
39 prilocaine, is described in human medicine to desensitise the skin before venepuncture to
40 make this procedure less aversive (Fetzer 2002; Rogers & Ostrow 2004). Flecknell et al
41 (1990) showed that the use of EMLA cream reduced the aversiveness of intravenous catheter
42 placement in laboratory dogs, cats and rabbits. Despite this study showing convincing
43 evidence of improved welfare, its use has not become standard practice in veterinary
44 medicine. One of the possible reasons why EMLA cream is not routinely used for IV catheter
45 placement in veterinary medicine might be the manufacturer's recommendation of a 60
46 minutes application time before attempting venepuncture. In a clinical environment, a 60
47 minutes waiting period might be considered too long. A study in children (Hopkins et al.
48 1988) has shown that the application time can be shortened to 30 minutes. However, no data
49 exist on the efficacy of EMLA cream after a 30 minutes application time in veterinary
50 medicine. We feel it is worthwhile to study the efficacy of EMLA cream after a 30 minutes
51 application time, as this shorter waiting period might make the routine use of EMLA cream
52 before IV catheter placement more feasible in clinical veterinary practice. Also, due to
53 patient, staff and environmental factors, the effect of EMLA might be less convincing or
54 absent in a clinical setting compared with the laboratory study of Flecknell et al (1990). We
55 therefore feel it is worthwhile to study the effect of EMLA in a clinical setting.

56 The aims of this study were to investigate the efficacy of EMLA cream in a busy
57 clinical setting and to assess whether there would be a difference in efficacy when using
58 either a 30 or 60 minutes application time. The objectives were to apply EMLA or a placebo

59 cream for either 30 or 60 minutes to client owned dogs scheduled for having an intravenous
60 catheter placed and to score the reaction of the dog to catheter placement. The hypothesis was
61 that, compared to placebo, EMLA cream would reduce the reaction of dogs to catheter
62 placement and that shortening the waiting time to 30 minutes would be as effective as a
63 waiting time of 60 minutes.

64

65 **Materials and methods**

66 The study was designed as a randomised, prospective, blinded clinical trial and was ethically
67 approved by the institutional animal welfare and ethics review board under the number
68 VIN/15/049.

69 *Subjects*

70 Two hundred and two (202) client owned dogs of mixed breeds were enrolled on the study
71 after the owners signed for informed consent. All dogs enrolled, needed IV catheter
72 placement for further treatment in our hospital. Dogs in which an IV catheter could not be
73 placed without sedation because of their character were excluded. No other exclusion criteria
74 were used. Dogs were randomly allocated to one of four experimental groups. Randomisation
75 was done in blocks of 16, n=4 per experimental group, and achieved by drawing a pre-printed
76 lot from an opaque envelope.

77 A specific power calculation has not been performed for this study, however,
78 consideration for group size has been performed a priori.

79

80 *Procedure*

81 Once allocated to an experimental group, the skin over either the cephalic vein or saphenous
82 vein was clipped and either EMLA cream (AstraZeneca, Luton, United Kingdom) or a
83 Placebo (E45 cream, Reckitt Benckiser Healthcare, Slough, United Kingdom) was applied at

84 a dose of approximately 1.5 grams of cream per 10 cm² of skin, according to the
85 manufacturer's instructions, and covered with an occlusive foil (kitchen cling film, B&M,
86 Liverpool, United Kingdom). The creams were left on for either 30 or 60 minutes. Treatment
87 for the different experimental groups was as follows: Group 1: After clipping, EMLA cream
88 was applied and left on for 60 minutes before placing an IV catheter; Group 2: After clipping,
89 EMLA cream was applied and left on for 30 minutes before placing an IV catheter; Group 3:
90 After clipping, Placebo cream was applied and left on for 60 minutes before placing an IV
91 catheter; Group 4: After clipping, EMLA cream was applied and left on for 30 minutes before
92 placing an IV catheter..

93 After the designated time had elapsed, the skin over the vein was cleared of cream and
94 prepped with chlorhexidine gluconate (ChloroPrep, BD, Basingstoke, United Kingdom).
95 Subsequently an intravenous catheter (BD, Basingstoke, United Kingdom, 18 - 24 Gauge)
96 was placed using a routine technique. Catheters were placed by members of staff (both
97 veterinary nurses and veterinary surgeons) and students (both veterinary nursing and
98 veterinary sciences students). Each dog was restrained by the primary investigator (), who
99 was blinded to group allocation until the final statistical analysis.

100

101 *Data recording*

102 The primary outcome recorded was the reaction of the dog to first venepuncture using
103 the scale as published by Flecknell et al (1990). Reaction 0: no reaction; Reaction 1: slight
104 movement of limb, tensing of muscles; Reaction 2: Limb withdrawal, attempt to move away;
105 Reaction 3: Marked attempts to escape, aggressive behaviour, vocalisation. The reaction was
106 scored by the primary investigator.

107 Data recorded for each dog were breed, gender, age, weight, body condition score,
108 and demeanour (1 = friendly, 2 = anxious, 3 = (fear) aggressive). Additional data recorded

109 were experience level of the catheter placer (novice, moderately experienced, experienced),
110 outcome of placing a catheter at the prepped site (success, fail), and number of attempts and
111 time needed to successfully place a catheter.

112

113 *Statistical analysis*

114 Continuous data of group demographics and experimental outcomes were analysed by one-
115 way ANOVA, followed by a Tukey post-hoc test when appropriate. The residuals from
116 parametric analyses were checked visually to ensure that they met the required assumptions
117 of normality of error and homogeneity of variance. Categorical data on group demographics
118 were analysed with a Chi-squared test. The primary outcome measure, reaction score, was
119 analysed using a Kruskal Wallis test followed by Mann Whitney tests of the multiple
120 pairwise comparisons, with p values adjusted using a Bonferroni correction. Statistical
121 significance was considered when $p < 0.05$. The statistics package IBM SPSS Statistics v24
122 (IBM Corporation, New York) was used for the analysis.

123

124 **Results**

125 In total, 202 dogs representing 55 breeds were successfully enrolled, (EMLA60: n=50;
126 EMLA30: n=51; Placebo 60: n=52; Placebo 30: n=49).

127 No differences between groups were found for age, weight, gender, body condition score, and
128 demeanour (table 1).

129 A contingency table of treatment by reaction score is shown in table 2. The Kruskal
130 Wallis test showed there to be an overall difference between treatment groups (Chi sq =
131 11.029, df = 3, $p = 0.012$). The pairwise comparisons showed there to be a lower overall
132 reaction score in the EMLA 60 group compared with the EMLA 30 group and the Placebo 60

133 group (adjusted $p = 0.018$ and adjusted $p = 0.044$, respectively). None of the other pairwise
134 comparisons were significant.

135 There was no effect of group allocation on the success rate to place an IV catheter at
136 the prepped site or the total number of attempts needed. However, level of experience did
137 have a significant effect on success rate ($p=0.001$), with novice placers having the highest
138 failure rate (40.9%) compared to moderately experienced (5.8%) and experienced (13.9%).
139 This was also reflected by the time needed to successfully place an IV catheter which was
140 significantly longer ($p<0.001$) for the novice group (211.5 +/- 35.4 seconds), compared with
141 the moderately experienced (56.5 +/- 11.5 seconds) and experienced (57.8 +/- 8.8 seconds)
142 groups.

143 The level of experience of the catheter placer did not differ between groups, and had
144 no effect on the reaction of the dog to first venepuncture.

145

146

147 **Discussion**

148 This study shows that EMLA cream applied for 60 minutes reduces the reaction of dogs to IV
149 catheter placement. This finding is consistent with previous findings of Flecknell et al (1990).

150 An interesting difference between the previous and present studies is that in the previous
151 study by Flecknell et al (1990) 16.6 % of dogs undergoing IV catheterisation in the placebo
152 group did not react to IV catheter placement. In contrast, in the present study 49.0% of dogs
153 in group Placebo 30 and 61.2% of dogs in group placebo 60 did not react IV catheter
154 placement. Several potential reasons can be put forward to explain this difference. First,
155 Flecknell et al studied a population of laboratory beagles who were likely used to the
156 surroundings and investigators carrying out the study. This study included dogs of different
157 breeds and backgrounds, inherently introducing variations in behavioural reactions to catheter

158 placement *per se*. Second, in the present study the dogs were newly admitted to the hospital
159 and not familiar with the handlers. The latter may have resulted in a certain level of stress
160 which might have obscured (sometimes subtle) signs of reaction or could have induced a
161 temporary state of stress induced analgesia (Bodnar 1986) reducing the aversity of the
162 procedure. Thirdly, the behavioural scale used to assess the reaction of the dogs can be
163 considered subjective. As the two studies were carried out by different investigators this
164 could have introduced differences in outcome. Nevertheless, both studies show that, in a
165 laboratory and a busy clinical setting respectively, EMLA cream applied for 60 minutes prior
166 to IV catheter placement reduced the incidence and severity of an aversive reaction to this
167 procedure in dogs and thus can be advocated to enhance the welfare of canine patients.

168 Less reaction of dogs might improve ease of catheter placement, however, the data
169 from this study show that the success rate of IV catheter placement was not enhanced by the
170 application of EMLA cream. Conversely, success was not decreased, either. This implies that
171 the occasionally cited fear of vasoconstriction after application of EMLA cream, leading to
172 greater difficulty to place an IV catheter (Schreiber et al. 2013), is unjustified. Other
173 concerns that have been cited for the use of EMLA cream in the clinical setting are the
174 development of local anaesthetic toxicity and methaemoglobinaemia. Although not assessed
175 in this study, previous studies in man and cats have shown that these problems were not
176 encountered during clinical use of EMLA cream (Wagner et al. 2006; Robieux et al. 1990).
177 Additionally, in none of the dogs in the present study were signs of local anaesthetic toxicity
178 observed. We therefore conclude that EMLA cream appears to have no negative side effects
179 in its clinical use and that fears for such effects should be discarded as reasons to not use
180 EMLA cream in the clinical setting.

181 E45 cream was used as a placebo in this study. The data sheet of E45 cream states
182 under side effect that 'Occasionally allergic reaction may occur'. This could make this cream

183 less suitable to use as a placebo. However, as we have not observed any form of allergic
184 reaction to either of the creams in any dog during this study, and since E45 cream resembles
185 EMLA cream in appearance and lacks the local anaesthetic effect, we feel it fulfilled the
186 purpose of placebo well. Indeed, this cream has been used before as a placebo cream in
187 human subjects without any reported problems (Speirs et al 2001).

188 A limitation of this study was that the level of experience of the catheter placers was
189 based on a self-judgement. The levels of experience therefore could have been biased by the
190 overall confidence level of the person asked. However, most people judging themselves as
191 novice were found to be truly novice as they had placed catheters only once or twice before.
192 Most of the moderately experienced people were end of year final year veterinary students,
193 whereas the people who judged themselves as experienced were very confident final year
194 students, nurses and anaesthetists. We therefore feel that the judgment of the level of
195 experience, although potentially biased, was accurate.

196 Novice catheter placers needed more attempts to successfully place an IV catheter
197 than moderately experienced and experienced ones. This might suggest that the use of EMLA
198 is particularly useful when inexperienced people perform the procedure. However, as the
199 level of experience of the catheter placer did not influence the reaction of the dog to first
200 venepuncture it seems that the use of EMLA cream can be advocated for placers of all levels
201 of experience.

202 A specific power calculation has not been performed for this study, however,
203 consideration for group size has been performed a priori. In a controlled laboratory study
204 with a uniform Beagle population, Flecknell et al (1990) demonstrated an effect of EMLA
205 cream with a sample size of 12 per group. This sets a lower limit for sample size. The
206 relatively innocuous consequences of the four treatments being applied allowed ready
207 expansion of sample size. Given the context of the current study which introduced a wide

208 range of extraneous, uncontrolled error variation, that would be found in a teaching hospital,
209 with a wide range of dog breeds being treated, sample size was maximised and constrained
210 only by the number of suitable dogs that were seen within the time limits of the study.

211 In conclusion, this is the first clinical study on the use of EMLA cream in dogs, and it
212 provides evidence that the routine use of EMLA cream in the clinical setting before
213 placement of and IV catheter in dogs improves their welfare. However, as the cream only
214 seems to be effective after being applied for 60 minutes, implementation only seems feasible
215 for elective/non-emergency cases.

216

217

218 **References**

219 Bodnar RJ (1986) Neuropharmacological and neuroendocrine substrates of stress-induced
220 analgesia. *Ann N Y Acad Sci* 467, 345-360.

221

222 Chebroux A, Leece EA, Brearley JC (2015) Ease of intravenous catheterisation in dogs and
223 cats: a comparative study of two peripheral catheters. *J Small Anim Pract* 56, 242-246.

224

225 Fetzer SJ (2002) Reducing venipuncture and intravenous insertion pain with eutectic mixture
226 of local anesthetic: a meta-analysis. *Nurs Res* 51, 119-124.

227

228 Flecknell PA, Liles JH, Williamson HA (1990) The use of lignocaine-prilocaine local
229 anaesthetic cream for pain-free venepuncture in laboratory animals. *Lab Anim* 24, 142-146.

230

231 Hopkins CS, Buckley CJ, Bush GH (1988). Pain-free injection in infants. Use of a
232 lignocaine-prilocaine cream to prevent pain at intravenous induction of general

233 anaesthesia in 1-5-year-old children. *Anaesthesia* 43, 198-201.

234

235 Robieux I, Kumar R, Radhakrishnan S (1991) Assessing pain and analgesia with a lidocaine-
236 prilocaine emulsion in infants and toddlers during venipuncture. *J Pediatr* 118, 971-973.

237

238 Rogers TL, Ostrow CL (2004) The use of EMLA cream to decrease venipuncture pain in
239 children. *J Pediatr Nurs* 19, 33-39.

240

241 Schreiber S, Ronfani L, Chiaffoni GP, et al. (2013) Does EMLA cream application interfere
242 with the success of venipuncture or venous cannulation? A prospective multicentre
243 observational study. *Eur J Pediatr* 172, 265-268.

244

245 Speirs AF, Taylor KH, Joanes DN, et al. (2001) A randomised, double-blind, placebo-
246 controlled, comparative study of topical skin analgesics and the anxiety and discomfort
247 associated with venous cannulation. *Br Dent J* 190, 444-449

248

249 Wagner KA, Gibbon KJ, Strom TL, et al. (2006) Adverse effects of EMLA
250 (lidocaine/prilocaine) cream and efficacy for the placement of jugular catheters in
251 hospitalized cats. *J Feline Med Surg* 8, 141-144.

252

253

254

255 Table 1. Demographic data of the dogs enrolled in the four different groups. BCS; body
 256 condition score. Demeanour; 1 = friendly, 2 = anxious, 3 = (fear) aggressive. Experience
 257 level of catheter placer; Nov = Novice, Mod = Moderately experienced, Exp = experienced
 258

Group	EMLA 60	EMLA 30	Placebo 60	Placebo 30
Age (months) mean +/- stdev	55.5 ± 43.1	57.6 ± 36.2	74.7 ± 41.7	67.4 ± 43.0
Weight (kg) mean +/- stdev	19.1 ± 15.4	15.9 ± 12.2	18.8 ± 11.4	22.7 ± 15.6
Gender N				
Male	31	32	24	31
Female	19	19	28	18
BCS (1 – 9) median (range)	5 (4-8)	5 (4-9)	5 (4-8)	5 (3-8)
Demeanour N				
1	46	43	43	42
2	4	8	9	7
3	0	0	0	0
Experience level N				
Nov	4	7	5	6
Mod	12	8	17	14
Exp	34	36	30	29

259

260

261 Table 2. Reaction of dogs to first venepuncture. Reaction 0: no reaction; Reaction 1: slight
 262 movement of limb, tensing of muscles; Reaction 2: Limb withdrawal, attempt to move away;
 263 Reaction 3: Marked attempts to escape, aggressive behaviour, vocalisation.

264

		Group allocation				
		EMLA	EMLA	Placebo	Placebo	
		60 ^a	30 ^b	60 ^b	30 ^{a,b}	
Reaction to first attempt	0	Count	38	25	27	30
		%	76.0%	49.0%	51.9%	61.2%
	1	Count	7	10	10	10
		%	14.0%	19.6%	19.2%	20.4%
	2	Count	3	7	6	6
		%	6.0%	13.7%	11.5%	12.2%
	3	Count	2	9	9	3
		%	4.0%	17.6%	17.3%	6.1%
	Total	Count	50	51	52	49
		%	100.0%	100.0%	100.0%	100.0%

265 Groups with different letters ^(a or b) are significantly different.